# A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

> **NCT01462851** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 51 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-05297909 25 mg
- **DRUG:** PF-05297909 100 mg
- **DRUG:** PF-05297909 250 mg
- **DRUG:** PF-05297909 525 mg
- **DRUG:** PF-05297909 525 mg

## Key facts

- **NCT ID:** NCT01462851
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462851, "A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01462851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*